<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="852">
  <stage>Registered</stage>
  <submitdate>14/09/2005</submitdate>
  <approvaldate>14/09/2005</approvaldate>
  <nctid>NCT00202306</nctid>
  <trial_identification>
    <studytitle>Indicated Prevention of Psychotic Disorders With Low-dose Lithium</studytitle>
    <scientifictitle>An Open-labeled, Parallel-group, Single-blinded (Rater) Pilot Study to Investigate the Neuroprotective Effects of of Low-dose Lithium in Young Subjects at Ultra High Risk (UHR) of Developing a First-episode Psychotic Disorder</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>E/01/028</secondaryid>
    <secondaryid>SMRI 01-038</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Schizophrenia</healthcondition>
    <healthcondition>Bipolar Disorder</healthcondition>
    <healthcondition>Psychotic Disorders</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Schizophrenia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Other mental health disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Depression</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Psychosis and personality disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - lithium carbonate

Treatment: drugs: lithium carbonate


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Symptomatic improvement</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Cognitive improvement</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Brain structural change (grey matter, ventricle to brain ratio)</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Brain metabolic changes (Proton Magnetic Resonance Spectroscopy)</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Transition rate to Psychosis</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of life</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>serum apoptosis parameters (eg. bcl2)</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Attenuated psychotic symptoms

          -  Self-limited brief psychotic episode

          -  Family History of psychosis and decrease in functioning over last year</inclusivecriteria>
    <inclusiveminage>15</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>30</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Organic causes of subthreshold psychotic symptoms (eg. epilepsy)

          -  More than one week of neuroleptic treatment</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/11/2001</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>30</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/12/2006</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>ORYGEN Youth Health, PACE Clinic - Parkville</hospital>
    <postcode>3052 - Parkville</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Melbourne Health</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Government body</othercollaboratortype>
      <othercollaboratorname>National Institute of Mental Health (NIMH)</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study investigates the neuroprotective properties of low-dose lithium in young
      individuals at ultra-high risk of developping a first psychotic episode. Fourty individuals
      having some symptoms of an emerging psychotic disorders (without meeting the threshold for a
      full-blown mental illness) will be treated with a low dose of lithium (about a third of the
      dose that is usually used to treat acute mania). We will assess the progression of the
      conditions of these individuals on a montly bases for a year. We will do behavioural,
      cognitive and imaging assessments prior start of the treatment, after three months and one
      year. We hope to demonstrate that low dose lithium will stop or even reverse the progression
      of disease. We expect that behavioral, cognitive and in vivo brain imaging parameters in
      those individuals treated with low dose lithium improve, compared to the monitoring group.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00202306</trialwebsite>
    <publication>Berger GE, Wood S, McGorry PD. Incipient neurovulnerability and neuroprotection in early psychosis. Psychopharmacol Bull. 2003 Spring;37(2):79-101. Review.
</publication>
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Gregor E Berger, MD</name>
      <address>University of Melbourne, Department of Psychiatry, ORYGEN Research Centre</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>